Five-year survival of advanced-stage ovarian cancer patients remains only 15--25%, despite intensive surgical treatment and combination chemotherapy. Development of intrinsic or acquired resistance to platinum-containing chemotherapy is the major obstacle in the treatment of patients with ovarian cancer ([Bhoola and Hoskins, 2006](#bib3){ref-type="other"}). Current clinicopathological prognostic factors do not allow individualised prediction of response to chemotherapy or disease outcome. Identification of molecular biological prognostic factors would be of great value for more accurately classification of ovarian carcinomas into subtypes with a different clinical outcome, thereby possibly also enabling individualised treatment strategies ([Crijns *et al*, 2006a](#bib15){ref-type="other"}).

Epidermal growth factor receptor (EGFR) and HER-2/neu are members of the erbB family of tyrosine kinase receptors. Aberrant activity of EGFR and HER-2/neu has been shown to be important in tumour growth and development. Binding of ligand to the ectodomain of ErbB receptors results in receptor autophosphorylation and initiation of downstream signalling cascades, such as the PI3K/AKT pathway and the Ras/Raf/MEK/Erk pathway. Activation of these pathways in cancer has been associated with increased angiogenesis, metastasis, dedifferentiation, growth and protection from apoptosis ([Yarden and Sliwkowski, 2001](#bib67){ref-type="other"}). Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) directly antagonises the PI3K/AKT pathway by preventing the phosphorylation of AKT ([Sansal and Sellers, 2004](#bib55){ref-type="other"}).

Several studies have shown that overexpression of HER-2/neu and EGFR, as well as alterations in their downstream targets AKT and extracellular signal-regulated kinase (ERK) is associated with resistance to platinum- and taxane-based chemotherapy. Treatment with agents directed against these proteins may enhance chemotherapy-induced cell death ([Ciardiello *et al*, 2000](#bib13){ref-type="other"}; [Altomare *et al*, 2004](#bib1){ref-type="other"}; [Qiu *et al*, 2005](#bib50){ref-type="other"}; [Lee *et al*, 2005b](#bib33){ref-type="other"}) The prognostic significance of EGFR and HER-2/neu has been extensively studied in ovarian cancer, but remains unclear. A recent meta-analysis revealed that abnormal expression of these markers appears to be associated with poor 5-year survival, but this is not a uniform finding ([Crijns *et al*, 2003](#bib17){ref-type="other"}).

The EGFR variant III (EGFRvIII) lacks exons 2--7 of the extracellular domain of the receptor. Although EGFRvIII is unable to bind ligand, it is constitutively phosphorylated and able to activate downstream signalling pathways ([Pedersen *et al*, 2001](#bib47){ref-type="other"}). EGFRvIII expression is thought to confer resistance to cisplatin and paclitaxel ([Nagane *et al*, 1998](#bib43){ref-type="other"}; [Montgomery *et al*, 2000](#bib40){ref-type="other"}). The two studies investigating EGFRvIII expression in ovarian cancer show conflicting results ([Moscatello *et al*, 1995](#bib42){ref-type="other"}; [Lassus *et al*, 2006](#bib30){ref-type="other"}).

The aim of the present study was to investigate the prognostic significance of EGFR and HER-2/neu, and their downstream targets AKT, ERK and PTEN in a large series of 232 epithelial ovarian cancer patients using the tissue microarray (TMA) platform. In addition to immunostaining, we determined the expression of EGFRvIII in more detail in a subset of 45 ovarian tumours using the more sensitive method RT--PCR.

Materials and methods
=====================

Patients
--------

Since 1985 all clinicopathological and follow-up data of 329 epithelial ovarian cancer patients treated at the University Medical Centre Groningen have been prospectively stored in a database. All patients gave informed consent for data storage and tumour collection, and studies were conducted in accordance with the Declaration of Helsinki principles and institutional review board policies. For the current study all consecutive chemonaive ovarian cancer patients for whom sufficient paraffin-embedded tumour tissue and complete follow-up data were available were selected (*n*=232).

Patients were surgically staged according to FIGO (International Federation of Gynaecology and Obstetrics) criteria ([Cancer Committee of the International Federation of Gynaecology and Obstetrics, 1986](#bib10){ref-type="other"}). Optimal and suboptimal debulking was defined as the largest residual tumour lesions having a diameter of \<2 cm or⩾2 cm. The histology of all carcinomas was determined by a gynaecological pathologist according to WHO (World Health Organization) criteria ([Scully, 2004](#bib58){ref-type="other"}).

Response to chemotherapy was evaluated according to WHO criteria ([World Health Organization, 1979](#bib66){ref-type="other"}). When indicated, intervention surgery was performed after three cycles of chemotherapy, while until 1996 second-look surgery was regularly performed after six cycles of chemotherapy.

TMA construction and immunostaining
-----------------------------------

Tissue microarrays were constructed as described previously ([de Graeff *et al*, 2006](#bib19){ref-type="other"}). In total, four tissue cores from 232 primary tumours and 45 paired tumours obtained at second-look surgery or surgery for recurrent disease were included on eight TMAs.

Antigen retrieval methods, primary antibodies and detection techniques are provided as [supplementary data](#sup1){ref-type="other"}. Sections (4 *μ*m) were de-paraffinised in xylene and endogenous peroxidase was blocked by incubation in 0.3% hydrogen peroxide for 30 min. After antigen retrieval, slides were incubated in normal goat serum (HER-2/neu), horse serum (EGFR, pEGFR), bovine serum (phosphorylated AKT (pAKT), phosphorylated ERK (pERK), PTEN, total AKT) or blocking solution (Dako, Cambridgeshire, UK) for EGFR. For pEGFR, pAKT, pERK and PTEN staining, endogenous avidin and biotin activity was blocked using a blocking kit (Vector Laboratories, Burlingame, UK). HER-2/neu staining was performed in a Dako autostainer (Dako). Staining was visualised by 3′3-diaminobenzidine tetrahydrochloride and sections were counterstained with haematoxylin. EGFRvIII staining was kindly performed by Dr A Jungbluth, Ludwig Institute for Cancer Research, New York, USA.

Positive controls included separate TMA slides containing multiple tumour and normal tissues for EGFR and pEGFR, sections from tumours with known marker expression for HER-2/neu and PTEN, ovarian cancer cell line A2780 for AKT, pAKT and ERK, and glioblastoma cell line U87 transfected with an EGFRvIII plasmid for EGFRvIII staining ([Jungbluth *et al*, 2003](#bib28){ref-type="other"}). Negative controls were obtained by omission of the primary antibody, and by incubation with normal rabbit IgG for total AKT. All control experiments gave satisfactory results. Antigen preservation was verified by vimentin staining, which was positive in all tumour and control samples.

Evaluation of immunostaining was independently performed by two observers (KAH and PDG), blinded to clinical data. The agreement between the two observers was\>90%. Discordant cases were reviewed with a gynaecological pathologist and were re-assigned on consensus of opinion.

HER-2/neu staining was scored according to the HercepTest protocol ([Lebeau *et al*, 2001](#bib31){ref-type="other"}), and was considered positive when\>10% of tumour cells showed moderate or strong membrane staining. For EGFR and EGFRvIII, tumours demonstrating\>10% membrane staining were considered to show overexpression ([Elie *et al*, 2004](#bib20){ref-type="other"}; [Skirnisdottir *et al*, 2004](#bib60){ref-type="other"}; [Cunningham *et al*, 2005](#bib18){ref-type="other"}). Overexpression of p-EGFR was defined as \>5% membrane or granular cytoplasmic staining ([Han *et al*, 2004](#bib25){ref-type="other"}). Tumours were considered positive for AKT or ERK if \>10% of tumour cells showed positive cytoplasmic and/or nuclear staining ([Kurose *et al*, 2001](#bib29){ref-type="other"}). Phosphatase and tensin homologue deleted on chromosome 10 staining in tumour sample was scored relative to staining in vascular endothelium ([Gimm *et al*, 2000](#bib23){ref-type="other"}; [Choe *et al*, 2003](#bib12){ref-type="other"}), and was regarded as negative when staining was completely absent in tumour tissue but present in vascular endothelium.

RT--PCR for EGFRvIII
--------------------

We performed RT--PCR analysis on a subset of 45 frozen tumour samples, of which 35 showed positive immunostaining for (p)EGFR or downstream targets and 10 were completely negative. Positive controls included a glioblastoma tumour sample expressing both the wild-type EGFR (wtEGFR) and EGFRvIII, and a cell line transfected with an EGFRvIII plasmid (Jurkat.EGFRvIII; [Bremer *et al*, 2005](#bib8){ref-type="other"}).

Extraction of RNA and cDNA synthesis was performed as previously described ([Crijns *et al*, 2006b](#bib16){ref-type="other"}). We performed RT--PCR separately for EGFRvIII and the housekeeping gene *GAPDH*. Primers were 5′-GGGCTCTGGAGGAAAAGAAA-3′ and 5′-AGGCCCTTCGCACTTCTTAC-3′ for amplifying EGFRvIII and wtEGFR ([Ji *et al*, 2006](#bib27){ref-type="other"}), and 5′-CACCCACTCCTCCACCTTTG-3′ and 5′-CCACCACCCTGTTGCTGTAG-3′ for amplifying *GAPDH*. The protocol was as follows: initial denaturation at 95°C for 10 min, followed by 30 (EGFRvIII) or 25 cycles (*GAPDH*) of amplification (1 min at 95°C, 1 min at 56°C for EGFRvIII and at 60°C for *GAPDH*, and 90 s at 72°C) and a final extension step at 72°C for 7 min. The RT--PCR products (128 bp for EGFRvIII, 929 bp for wtEGFR and 110 bp for *GAPDH*) were visualised by 1.5% agarose gel electrophoresis in 1 × Tris-Borate EDTA buffer.

Statistical analysis
--------------------

Statistical analysis was carried out using the SPSS 12.01 software package. Cut-off points for positive marker expression were determined *a priori*. All cases with \<2 evaluable cores were excluded from analysis.

Comparisons between paired tumour samples obtained before and after chemotherapy were made using the Wilcoxon rank sum test. Associations between markers, and between markers and clinicopathological characteristics were performed using the *χ*^2^ or Fisher\'s exact test, where appropriate.

The end points investigated were progression-free and disease-specific overall survival (PFS and OS), defined as the time from primary surgery until progression/relapse of the disease or death of ovarian cancer, respectively. Response to platinum-based chemotherapy could only be evaluated in patients who had measurable disease after primary surgery and/or during first-line chemotherapy (*n*=130), and was defined according to WHO criteria ([World Health Organization, 1979](#bib66){ref-type="other"}).

For univariate and multivariate survival analysis Cox proportional hazards model was used. Categorised covariates that were significant in univariate analysis were entered simultaneously into the multivariate model. Response to chemotherapy was analysed using logistic regression analysis. For this analysis, response was entered as a categorical variable (complete and partial response *vs* stable and progressive disease). *P*-values \<0.05 were considered statistically significant.

Results
=======

Patients
--------

A total of 232 patients (median age 57.8 years, range 22--90) treated at the Groningen University Medical Centre between 1985 and 2002 were selected for the present study ([Table 1](#tbl1){ref-type="table"}). Of them 64 (27.6%) patients presented with stage I/II disease and 166 (71.5%) patients with stage III/IV disease. Optimal debulking was achieved in 61 (96.8%) stage I/II patients and 48 (31.0%) stage III/IV patients. First-line chemotherapy regimens were platinum based in 100 (43.1%) patients and platinum- and taxane-based in 72 (31.0%) patients. Total 25 (10.8%) patients were treated with other regimens, and 32 (13.8%) patients did not receive chemotherapy because of stage Ia disease, comorbidity or treatment refusal.

For stage I/II patient, 5-year PFS was 73.0% (median 53 months, range 0--207) and 5-year OS was 78.9% (median 58 months, range 0--207). For stage III/IV patients, 5-year PFS was 13.8% (median 13.8 months, range 0--149) and 5-year OS was 22.3% (median 21 months, range 0--213). Five-year survival for the whole cohort was 39.2%.

Immunostaining and RT--PCR
--------------------------

The number of non-evaluable primary tumours due to core loss during staining procedures or absence of tumour tissue ranged from 2 (0.9%) for HER-2/neu staining to 10 (4.3%) for pERK staining. Positive staining was present in 6.2% of tumours for EGFR, 5.1% of tumours for HER-2/neu, 11.8% tumours for pEGFR, 100% of tumours for total AKT, 8.3% of tumours for pAKT and 36.9% of tumours for pERK ([Table 2](#tbl2){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}). Of 224 tumours, 69 (30.8%) showed completely negative PTEN staining. None of the tumour samples stained positive for EGFRvIII, nor could EGFRvIII be detected by RT--PCR. Staining for pERK was more frequent in tumour samples obtained after three or six cycles of chemotherapy compared to paired primary tumour samples (65 *vs* 37%, *P*=0.020). For all other proteins, staining patterns in primary tumours were comparable to paired residual or recurrent tumour samples ([Table 2](#tbl2){ref-type="table"}).

Unexpectedly, PTEN staining was positively correlated with pAKT staining (*P*=0.034). No associations were found between other proteins (data not shown).

Clinicopathological characteristics
-----------------------------------

Overexpression of EGFR was more frequent in non-serous tumours (*P*=0.017; [Table 3](#tbl3){ref-type="table"}). Stage III/IV tumours more often showed overexpression of pAKT (*P*=0.029). Loss of PTEN was related to stage I/II disease (*P*=0.006). Furthermore, negative PTEN immunostaining was associated with non-serous tumour type (*P*=0.042), occurring in 25% of serous, 39% of endometrioid, 42% of mucinous and 56% of clear cell tumours. No other associations between protein expression and clinicopathological variables were found.

Response to chemotherapy and survival
-------------------------------------

Univariate Cox regression analysis revealed that patients with a PTEN-negative tumour had a better PFS and OS ([Table 4](#tbl4){ref-type="table"}; *P*\<0.001 and *P*=0.037, respectively). On the basis of recent publications dividing ovarian carcinomas into subgroups with specific molecular alterations ([Bell, 2005](#bib2){ref-type="other"}; [Press *et al*, 2008](#bib48){ref-type="other"}), we performed subgroup analyses for early and late stage patients, and for patients with grade III and undifferentiated carcinomas. Subgroup analysis for stage I/II and stage III/IV patients showed that PTEN predicts PFS only in the early stage group (HR 0.29, 95% CI 0.095--0.9, *P*=0.032 for stage I/II patients, HR 0.74, 95% CI 0.48--1.15, *P*=0.18 for stage III/IV patients). Loss of PTEN also predicted improved PFS in 91 poorly differentiated serous carcinomas, of which 20 (22.0%) were PTEN negative (HR 0.43, 95% CI 0.23--0.83, *P*=0.011).

In multivariate analysis PTEN staining (*P*=0.015), FIGO stage (*P*=0.013) and residual tumour after primary surgery (*P*\<0.001) independently predicted PFS ([Table 5](#tbl5){ref-type="table"}). Tumour stage (*P*=0.023) and residual tumour (*P*\<0.001), but not PTEN staining (*P*=0.833) were significant prognostic factors in multivariate analysis for OS. Other markers were not associated with survival. Protein expression did not predict response to platinum-based chemotherapy.

Discussion
==========

Our study in a large, well-defined series of epithelial ovarian cancer patients shows that PTEN-negative tumours might represent a subgroup of ovarian carcinomas with a relatively favourable prognosis. To our knowledge this is the first study describing a relationship between negative PTEN staining and improved survival in ovarian cancer. Although a relationship between negative PTEN staining and improved survival has been described for endometrial cancer patients ([Risinger *et al*, 1998](#bib51){ref-type="other"}), previous studies in ovarian cancer found no or an inverse relationship between PTEN and prognosis ([Schondorf *et al*, 2003](#bib57){ref-type="other"}; [Wang *et al*, 2005](#bib65){ref-type="other"}; [Lee *et al*, 2005a](#bib32){ref-type="other"}). These contrasting results could be explained by the fact that previous studies either did not have the power to evaluate possible relations with survival, or restricted their analysis to stage III/IV ovarian cancer patients. In the current study PTEN staining was of prognostic significance mainly in the stage I/II group and in poorly differentiated serous carcinomas.

We found negative PTEN expression in 30.8% of tumours, which is in agreement with previous studies ([Wang *et al*, 2005](#bib65){ref-type="other"}; [Lee *et al*, 2005a](#bib32){ref-type="other"}; [Hashiguchi *et al*, 2006](#bib26){ref-type="other"}). In ovarian cancer, loss-of-heterozygosity (LOH) at the PTEN locus (10q23.3) occurs in 31--45% of tumours, whereas mutations of the second PTEN allele are relatively rare ([Maxwell *et al*, 1998](#bib36){ref-type="other"}; [Obata *et al*, 1998](#bib45){ref-type="other"}; [Kurose *et al*, 2001](#bib29){ref-type="other"}). Loss of protein expression is therefore also thought to arise through other mechanisms, such as DNA methylation ([Sansal and Sellers, 2004](#bib55){ref-type="other"}).

Interestingly, we showed a high rate of negative PTEN staining in endometrioid and clear cell tumours. A high rate of PTEN loss in clear cell and endometrioid carcinomas has also been shown in previous, much smaller studies ([Obata *et al*, 1998](#bib45){ref-type="other"}; [Hashiguchi *et al*, 2006](#bib26){ref-type="other"}). Both cancers are thought to at least partly arise from endometriosis. [Sato *et al* (2000)](#bib56){ref-type="other"} showed that in three out of five ovarian carcinomas associated with endometriosis, LOH at 10q23.3 occurs in both the carcinoma and in endometriotic lesions, implicating that LOH is an early event in carcinogenesis and that PTEN is involved in the progression from endometriotic precursor lesion to clear cell or endometrioid ovarian cancer.

Our results show that negative PTEN staining is strongly associated with early stage disease and a non-serous tumour type. Recent studies suggest that ovarian carcinomas could be divided in two categories. The first category, called type I, includes low-grade serous, mucinous, clear cell and endometrioid tumour with frequent alterations in BRAF, KRAS and PTEN. Type I tumours are thought to arise from precursor lesions such as endometriosis and have a relatively good prognosis. In contrast, type II tumours, including high-grade serous and undifferentiated carcinomas characterised by p53 mutations and overexpression/amplification of HER-2/neu and AKT2, tend to show a highly aggressive behaviour ([Shih and Kurman, 2004](#bib59){ref-type="other"}; [Bell, 2005](#bib2){ref-type="other"}). In the present study, we identified a relationship of pAKT expression with late stage disease. Moreover, our previous work showed that overexpression of p53 mostly occurs in high-grade, late stage, serous carcinomas ([de Graeff *et al*, 2006](#bib19){ref-type="other"}). Our combined results therefore support this model of ovarian carcinogenesis.

A recent study by [Press *et al* (2008)](#bib48){ref-type="other"} suggests that type II ovarian tumours can be subclassified into three groups based on their BRCA1 status. Their results indicate that poorly differentiated serous carcinomas with BRCA1 mutations frequently show loss of PTEN. The molecular mechanism underlying the relationship between loss of PTEN and BRCA1 mutations in ovarian cancer remains unknown. Possibly, ineffective DNA repair in BRCA1-linked tumours results in specific mutations of the *PTEN* gene ([Foulkes, 2008](#bib22){ref-type="other"}; [Saal *et al*, 2008](#bib52){ref-type="other"}). On the basis of these observations we performed survival analysis in a subgroup of 91 poorly differentiated serous carcinomas. We were able to show that loss of PTEN was indeed associated with improved PFS in this subgroup of ovarian carcinomas. Patients with BRCA1-linked hereditary tumours have a favourable survival compared to sporadic tumours, possibly because of a good response to chemotherapy ([Boyd *et al*, 2000](#bib7){ref-type="other"}; [Chetrit *et al*, 2008](#bib11){ref-type="other"}). The link between PTEN and BRCA1 status might therefore explain an improved disease outcome in a subgroup of patients with an otherwise very poor prognosis. In that case, IHC staining of PTEN may be a rapid way of identifying tumours most likely to carry BRCA1 mutations. Subsequently, those patients might benefit from treatments with agents selectively targeting BRCA mutant tumour cells, such as poly(ADP-ribose) polymerase 1 inhibitors ([Farmer *et al*, 2005](#bib21){ref-type="other"}).

In the current study, loss of PTEN was associated with improved PFS, but not OS. As PFS is closely related to response to chemotherapy, these results might indicate that patients with PTEN negative tumours respond favourably to first-line therapy. In the current study we did not observe a relationship between PTEN status and response to chemotherapy. However, this analysis was limited to patients who had measurable disease before start of chemotherapy or measurable disease progression during treatment. Response to chemotherapy could therefore only be analysed in a subset of advanced-stage patients with a very poor prognosis. One possible explanation for the lack of association between negative PTEN staining and OS might be explained by the fact that tumours can acquire secondary mutations during or after platinum-based chemotherapy ([Sakai *et al*, 2008](#bib54){ref-type="other"}). Once a patient presents with progressive or recurrent disease, these mutations may render the tumour insensitive to platinum-based chemotherapy irrespective of the PTEN status.

We did not observe any association between EGFR and HER-2/neu immunostaining and disease outcome, confirming results of a previous study also from our institution ([Van Der Zee *et al*, 1995](#bib64){ref-type="other"}). Previous studies on the relationship between EGFR or HER-2/neu overexpression and clinicopathological characteristics, response to chemotherapy and survival have shown conflicting results ([Camilleri-Broet *et al*, 2004](#bib9){ref-type="other"}; [Elie *et al*, 2004](#bib20){ref-type="other"}; [Nielsen *et al*, 2004](#bib44){ref-type="other"}; [Psyrri *et al*, 2005](#bib49){ref-type="other"}). One of the most important reasons for these inconclusive data is the considerable methodological variability among studies ([Hall *et al*, 2004](#bib24){ref-type="other"}). Techniques used to determine marker expression, antibodies and scoring systems used for immunostaining vary widely between studies. For the present investigation, we aimed to use well-characterised antibodies that have been extensively studied in other tumour types, and, if possible, used well-defined scoring criteria that have been shown to be reproducible. We have sought to adhere to the REMARK guidelines for publishing prognostic factor studies ([McShane *et al*, 2005](#bib37){ref-type="other"}). The use of these guidelines and of standardised methods should aid in increasing transparency and reproducibility of prognostic factor studies in ovarian cancer and other tumour types.

As tumours showing evidence of strong signalling through a particular pathway are thought to have a high chance of responding to therapies directed against this pathway, the identification of reliable biomarkers could aid in selecting patients who are most likely to benefit from targeted therapy ([Bild *et al*, 2006](#bib4){ref-type="other"}). Results of different clinical trials show that positive immunostaining for HER-2/neu or EGFR does not reliably predict response to ErbB-targeted therapy ([Ciardiello and Tortora, 2008](#bib14){ref-type="other"}). A possible better marker of response to EGFR- and HER-2/neu-targeted therapies is activation or downregulation of downstream pathways. Indeed, positive immunostaining for pAKT, pERK, PTEN and EGFRvIII has been reported to predict sensitivity to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and glioblastoma ([Han *et al*, 2004](#bib25){ref-type="other"}; [Mellinghoff *et al*, 2005](#bib38){ref-type="other"}). The association of pAKT and pERK in relation to response to ErbB-targeted therapy in ovarian cancer has not been studied yet, but expression of these proteins might be used as a marker of responsiveness to targeted therapies. Our results show that 8.3 and 36.9% of tumours show positive pAKT and pERK staining, respectively, indicating that only a subgroup of patients might benefit from agents directed against these pathways. As pERK is overexpressed in approximately one-third of primary ovarian tumours and 65% of tumour samples from primary chemo-resistant tumours obtained after chemotherapy, treatment of patients with Ras/Raf/MEK/Erk-targeted agents appears to be an interesting therapeutic option ([Messersmith *et al*, 2006](#bib39){ref-type="other"}).

In contrast to previous studies, we show a low percentage of pAKT-positive tumours ([Altomare *et al*, 2004](#bib1){ref-type="other"}; [Wang *et al*, 2005](#bib65){ref-type="other"}). The discrepancy between our results and those obtained in previous studies is not likely to be due to methodological variability. We have used the same well-characterised antibody that was used in previous studies, with a comparable staining protocol. In all our experiments, the ovarian cancer cell line A2780 served as a positive control. Expression of pAKT in this cell line was confirmed by western blotting (data not shown). In agreement with previous large studies, we also show a relatively low percentage of EGFR- and HER-2/neu-overexpressing tumours ([Bookman *et al*, 2003](#bib6){ref-type="other"}; [Lassus *et al*, 2006](#bib30){ref-type="other"}). We therefore conclude that in this group of ovarian carcinomas, signalling of EGFRs via the AKT pathway might be important only in specific subgroups of ovarian tumours.

Surprisingly, we identified a significant relationship between positive expression of AKT and positive expression of PTEN. The role of PTEN as a negative regulator of AKT is well documented in both cell line models and tumour samples ([Stambolic *et al*, 1998](#bib62){ref-type="other"}; [Sun *et al*, 1999](#bib63){ref-type="other"}; [Kurose *et al*, 2001](#bib29){ref-type="other"}; [Choe *et al*, 2003](#bib12){ref-type="other"}). However, others have also identified a positive correlation between expressions of the two proteins by immunostaining ([Panigrahi *et al*, 2004](#bib46){ref-type="other"}; [Slipicevic *et al*, 2005](#bib61){ref-type="other"}; [Wang *et al*, 2005](#bib65){ref-type="other"}). This might mean that in tumours, the regulatory relationship between AKT and PTEN is not linear. In breast and ovarian cancer, it has been shown that aberrations of the *PI3K* and *PTEN* genes are mutually exclusive ([Saal *et al*, 2005](#bib53){ref-type="other"}; [Press *et al*, 2008](#bib48){ref-type="other"}), resulting in constitutive activation of the PI3K pathway in the presence of an intact PTEN. Loss of PTEN may also contribute to tumourigenesis and progression via AKT-independent pathways, such as the p53 pathway ([Blanco-Aparicio *et al*, 2007](#bib5){ref-type="other"}).

In contrast to available data in literature we did not detect any EGFRvIII in this large group of ovarian carcinomas. Moscatello *et al* reported that EGFRvIII is expressed in 75% of ovarian tumours, but this high percentage could not be confirmed in subsequent studies ([Jungbluth *et al*, 2003](#bib28){ref-type="other"}; [Lassus *et al*, 2006](#bib30){ref-type="other"}). We determined EGFRvIII status by immunohistochemistry using the well-defined antibody DH8.3 and verified our results at the RNA level by RT--PCR on a subset of 45 tumours showing positive immunostaining for EGFR or downstream targets. As EGFRvIII heterodimerises with wtEGFR, is constitutively phosphorylated and activates AKT and to a lesser extent ERK, we hypothesised that the chance of finding EGFRvIII-positive tumours was largest in this subgroup ([Montgomery *et al*, 1995](#bib41){ref-type="other"}; [Li *et al*, 2004](#bib34){ref-type="other"}; [Luwor *et al*, 2004](#bib35){ref-type="other"}). As we did not detect any EGFRvIII positivity in this subgroup, nor in 10 tumours that did not overexpress any of the studied markers, our data strongly suggest that EGFRvIII signalling does not play a major role in ovarian cancer.

In the current retrospective study we investigated protein expression in a large well-defined patient population. However, our results showed that protein expression was mainly important in specific patient groups. Unfortunately, these subgroups were too small to perform valid multivariate analysis. Furthermore, not all patients received the same chemotherapeutic treatment. Future studies should determine the prognostic value of PTEN staining, especially in early stage patients and poorly differentiated serous tumours, in large prospective studies including homogeneously treated patients.

In summary, we demonstrated that negative PTEN staining is associated with favourable patient and tumour characteristics, and independently predicts improved PFS. The importance of pAKT and pERK expression as downstream markers of responsiveness to receptor tyrosine kinase-targeted therapies deserves to be evaluated in clinical trials. A better understanding of these pathways and their role in ovarian cancer will enable us to use targeted drugs more efficiently, and to identify (groups of) genes that predict prognosis more accurately.

External data objects {#sup1}
=====================

###### Supplementary data

[Supplementary Information](#sup1){ref-type="other"} accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

![Results of immunostaining. (**A**) and (**B**) show positive immunostaining for epidermal growth factor receptor (EGFR) and pEGFR, respectively, in the same tumours. Positive immunostaining for pAKT and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in the same tumour is shown in (**C**) and (**D**), respectively. Figures (**E**--**G**) show positive immunostaining for EGFRvIII (positive control, **E**), HER-2/neu (**F**), pERK (**G**) and total AKT (**H**).](6604471f1){#fig1}

###### 

Clinicopathological characteristics

                           **All patients (*n*=232)**   
  ------------------------ ---------------------------- ------
  *FIGO stage*                                           
   Stage I                 45                           19.4
   Stage II                19                           8.2
   Stage III               133                          57.3
   Stage IV                33                           14.2
   Missing                 2                            0.9
                                                         
  *Tumour type*                                          
   Serous                  129                          55.6
   Mucinous                27                           11.6
   Clear cell              17                           7.3
   Endometrioid            33                           14.2
   Adenocarcinoma NOS      9                            3.9
   Other                   17                           7.3
                                                         
  *Tumour grade*                                         
   Grade I                 39                           16.8
   Grade II                51                           22.0
   Grade III               104                          44.8
   Undifferentiated        14                           6.0
   Missing                 24                           10.3
                                                         
  *Residual disease*                                     
   \<2 cm                  111                          47.8
   ⩾2 cm                   109                          47.0
   Missing                 12                           5.2
                                                         
  *Type of chemotherapy*                                 
   No chemotherapy         32                           13.8
   Platinum based          100                          43.1
   Platinum/taxane based   72                           31.0
   Other regimen           25                           10.8
   Missing                 3                            1.3

FIGO= International Federation of Gynaecology and Obstetrics; NOS=not otherwise specified.

###### 

Results of immunostaining

                                   **EGFR**      **pEGFR**    **HER-2/neu**    **pAKT**      **pERK**      **PTEN**
  ------------------------------ ------------- ------------- --------------- ------------- ------------- -------------
  *Primary tumours (*n=*232)*                                                                            
   Evaluable^a^                       228           228            230            228           222           224
   Positive                        16 (7.0%)    27 (11.8%)      12 (5.2%)      19 (8.3%)    82 (36.9%)    155 (69.2%)
   Negative                       212 (93.0%)   201 (88.2%)    218 (94.8%)    209 (91.7%)   140 (63.1%)   69 (30.8%)
                                                                                                                
  *Second look (*n=*26)*                                                                                 
   Evaluable^a^                       22            22             22             21            20            19
   Positive                        4 (18.2%)     5 (22.7%)      1 (4.5%)       4 (19.0%)    13 (65.0%)    16 (84.2%)
   Negative                       18 (81.8%)    17 (77.3%)     21 (95.5%)     17 (81.0%)     7 (35.0%)     3 (15.8%)
   *P*-value^b^                      0.317         0.317          1.000          0.317       **0.020**       0.655
                                                                                                                
  *Recurrent disease (*n=*19)*                                                                           
   Evaluable^a^                       19            19             18             18            19            18
   Positive                        2 (10.5%)     3 (15.8%)      2 (11.1%)      3 (16.7%)     8 (42.1%)    17 (94.4%)
   Negative                       17 (89.5%)    16 (84.2%)     16 (88.9%)     15 (83.3%)    11 (57.9%)     1 (5.6%)
   *P*-value^c^                      0.317         0.564          0.157          0.317         0.317         0.317

Bold signifies *P*\<0.05.

Number of evaluable cases (cases with \<2 evaluable cores were excluded from the analysis).

*P*-value from Wilcoxon rank sum test for comparison of protein expression between tumour samples from primary surgery and from second look.

*P*-value from Wilcoxon rank sum test for comparison of protein expression between tumour samples from primary surgery and surgery for recurrent disease.

###### 

Relationship between proteins and clinicopathological characteristics

                   **HER2**   **EGFR**   **pEGFR**   **pAKT**   **pERK**   **PTEN**                                                                                                     
  --------------- ---------- ---------- ----------- ---------- ---------- ---------- --------- -------- ------ ---------- -------- ------- --------- -------- ------ -------- --------- -------
  *Age*                                                                                                                                                                                     
   \<58 years      110/113     3/113       0.14      106/112     6/112       0.44     99/113    14/113   0.84   104/114    10/114   1.00    69/108    39/108   0.89   38/111   73/111    0.31
   \>58 years      108/117     9/117                 106/116     10/116               102/115   13/115          105/114    9/114            71/114    43/114          31/113   82/113       
                                                                                                                                                                                            
  *Stage*                                                                                                                                                                                   
   Early            59/62       3/62     1.00^\*^     56/61       5/61     0.77^\*^    51/60     9/60    0.49    60/91      1/61    0.029    38/59    21/59    0.88   27/60     33/60    0.006
   Late            157/166     9/166                 154/165     11/165               148/166   18/166          147/165    18/165           101/161   60/161          41/162   121/162      
                                                                                                                                                                                            
  *Histology*                                                                                                                                                                               
   Serous          123/128     5/128       0.38      123/127     4/127      0.017     111/127   16/127   0.84   115//126   11/126   1.00    77/123    46/123   0.89   31/124   93/124    0.042
   Other            95/102     7/102                  89/101     12/101               90/101    11/101           94/102    8/102             63/99    36/99           38/100   62/100       
                                                                                                                                                                                            
  *Grade*                                                                                                                                                                                   
   I/II             84/89       5/89     1.00^\*^     82/87       5/87       0.78      75/88    13/88    0.18    85/89      4/89    0.19     49/85    36/85    0.24   32/87     55/87    0.17
   III/undiff      112/118     6/118                 109/118     9/118                107/117   10/117          104/116    12/116           76/114    38/114          31/114   83/114       
                                                                                                                                                                                            
  *Res. tumour*                                                                                                                                                                             
   \<2 cm          105/109     4/109       0.54      100/107     7/107       1.00     95/107    12/107   0.84   102/108    6/108    0.31    70/102    32/102   0.15   34/104   70/104    0.55
   ⩾ 2 cm          102/109     7/109                 101/109     8/109                95/109    14/109           97/108    11/108           63/108    45/108          31/108   77/108       

Neg=negative; Pos=positive; Res. tumour=residual tumour after primary surgery; undiff=undifferentiated.

*P*-values are derived from the *χ*^2^-test or Fischer\'s exact test, where appropriate (^\*^signifies the use of the Fischer\'s exact test).

###### 

Results of univariate survival analysis

                                **Univariate Cox regression analysis**                         
  ----------------------------- ---------------------------------------- --------------------- -------------
  *Progression-free survival*                                                                  
   EGFR positive                0.55                                          0.26--1.17       0.12
   HER-2/neu positive           0.98                                          0.46--2.10       0.96
   pEGFR positive               0.62                                          0.35--1.06       0.09
   pAKT positive                0.88                                          0.46--1.67       0.69
   pERK positive                1.09                                          0.77--1.54       0.64
   PTEN negative                **0.48**                                  **0.32**--**0.72**   **\<0.001**
                                                                                                
  *Overall survival*                                                                            
   EGFR positive                0.84                                          0.43--1.65       0.43
   HER-2/neu positive           1.02                                          0.48--2.20       0.94
   pEGFR positive               0.64                                          0.36--1.39       0.13
   pAKT positive                1.05                                          0.58--1.91       0.86
   pERK positive                1.04                                          0.73--1.48       0.84
   PTEN negative                **0.66**                                  **0.44**--**0.097**  **0.037**

Bold signifies *P*\<0.05.

###### 

Results of multivariate survival analysis

                                  **Multivariate Cox regression analysis**                        
  ------------------------------- ------------------------------------------ -------------------- -------------
  *Progression-free survival*                                                                     
   PTEN-negative tumour           **0.57**                                    **0.36**--**0.90**  **0.015**
   Age\>58 years                  1.09                                            0.74--1.60      0.671
   FIGO stage III/IV              **2.51**                                    **1.21**--**5.19**  **0.013**
   Serous tumour type             1.44                                            0.92--2.24      0.109
   Differentiation grade III/IV   1.40                                            0.89--2.19      0.144
   Suboptimal debulking           **2.37**                                    **1.43**--**3.50**  **\<0.001**
                                                                                                   
  *Overall survival*                                                                               
   PTEN-negative tumour           0.96                                            0.62--1.47      0.833
   Age\>58 years                  1.24                                            0.83--1.83      0.291
   FIGO stage III/IV              **2.56**                                    **1.14**--**5.74**  **0.023**
   Serous tumour type             1.46                                            0.93--2.76      0.100
   Differentiation grade III/IV   1.50                                            0.94--2.38      0.090
   Suboptimal debulking           **2.51**                                    **1.57**--**4.00**  **\<0.001**

PTEN=phosphatase and tensin homologue deleted on chromosome 10; FIGO=International Federation of Gynaecology and Obstetrics.

Bold signifies *P*\<0.05.
